Vonjo (pacritinib) is a novel kinase inhibitor approved by the U.S. Food and Drug Administration (FDA), providing a new treatment option for patients with specific types of myelofibrosis.
What is Vonjo (Pacritinib)?
Pharmacological Actions
Pacritinib is an oral kinase inhibitor.
It primarily exhibits inhibitory activity against wild-type Janus-associated kinase 2 (JAK2), mutant JAK2V617F, FMS-like tyrosine kinase 3 (FLT3), and interleukin-1 receptor-associated kinase 1 (IRAK1).
These targets are involved in the signal transduction of various cytokines and growth factors, and play an important role in hematopoiesis and immune function.
Pacritinib can also inhibit activin A receptor type 1/activin receptor-like kinase 2 (ACVR1/ALK2).
At clinically relevant concentrations, pacritinib does not inhibit JAK1, and its inhibitory activity against JAK2 is higher than that against JAK3 and tyrosine kinase 2 (TYK2).
Indications
Pacritinib is indicated for the treatment of adult patients with intermediate- or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis who have a platelet count below 50×10⁹/L.
This indication is approved under accelerated approval based on spleen volume reduction, and its continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials.
Specifications and Properties of Vonjo (Pacritinib)
Preparation Specifications
Each capsule contains 100 mg of pacritinib (equivalent to 140.65 mg of pacritinib citrate).
Packaging specification: 120 capsules per bottle.
Physical Properties
Capsule appearance: Hard, oval-shaped, opaque gelatin capsules with a scarlet cap and a gray body.
Marking information: The cap is imprinted with "Pacritinib 100mg", and the body is imprinted with "C78837".
Capsule components: Gelatin, titanium dioxide, iron oxide black, erythrosine, iron oxide red.
Printing ink components: Shellac, propylene glycol, titanium dioxide, sodium hydroxide, and povidone.
Excipient Composition
Microcrystalline cellulose
Polyethylene glycol 8000 (PEG 8000).
Magnesium stearate
Storage Conditions of Vonjo (Pacritinib).
Storage Environment
Pacritinib should be stored at room temperature, with the temperature maintained below 30°C (86°F).
To ensure drug stability, the bottle must be tightly closed and stored away from light.
The drug should be stored in its original packaging, and original packaging or light-resistant containers must also be used during distribution.
Precautions for Use
During the use of pacritinib, patients must manage the medication strictly in accordance with the guidance of healthcare professionals.
Capsules should be swallowed whole; do not open, break, or chew them.
The drug can be taken with or without food, twice daily, approximately at the same times each day.
If a dose is missed, skip the missed dose and take the next dose at the regularly scheduled time. Do not take two doses at once to make up for the missed dose.
